ABSTRACT
Background Electronic health records (EHRs) and big data tools offer the opportunity for surveillance of adverse events (patient harm associated with medical care). We chose the case of transfusion adverse events (TAEs) and potential TAEs (PTAEs) because 1.) real dates were obscured in the study data, and 2.) there was emerging recognition of new types during the study data period.
Objective We aimed to use the structured data in electronic health records (EHRs) to find TAEs and PTAEs among adults.
Methods We used 49,331 adult admissions involving critical care at a major teaching hospital, 2001-2012, in the MIMIC-III EHRs database. We formed a T (defined as packed red blood cells, platelets, or plasma) group of 21,443 admissions vs. 25,468 comparison (C) admissions. The ICD-9-CM diagnosis codes were compared for T vs. C, described, and tested with statistical tools.
Results TAEs such as transfusion associated circulatory overload (TACO; 12 T cases; rate ratio (RR) 15.61; 95% CI 2.49 to 98) were found. There were also PTAEs similar to TAEs, such as fluid overload disorder (361 T admissions; RR 2.24; 95% CI 1.88 to 2.65), similar to TACO. Some diagnoses could have been sequelae of TAEs, including nontraumatic compartment syndrome of abdomen (52 T cases; RR 6.76; 95% CI 3.40 to 14.9) possibly being a consequence of TACO.
Conclusions Surveillance for diagnosis codes that could be TAE sequelae or unrecognized TAE might be useful supplements to existing medical product adverse event programs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research was done with FDA support and under contract HHSF223201510027B between FDA and Booz Allen Hamilton Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
On behalf of the Food and Drug Administration Institutional Review Board (FDA IRB), Karen Ulisney, MSN, CRNP, Human Subject Protection (HSP) Executive Officer, stated the study "does not require FDA IRB review and approval because it is not research involving human subjects as defined in 45 CFR part 46 and it is not an FDA-regulated clinical investigation, as defined in 21 CFR part 56.” Patients/participants were never identified to the authors. The creators of the research dataset at the Massachusetts Institute of Technology (MIT) met the MIT Institutional Review Board requirements. This was not a clinical trial or interventional study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Original data (MIMIC-III) are available from https://mimic.physionet.org/about/mimic/ after receiving their permission.
ABBREVIATIONS USED MORE THAN ONCE
- 95% LCL
- normal approximate 95% lower confidence limits 95%
- UCL
- normal approximate 95% upper confidence limits
- AE
- adverse events
- C
- comparison group of admissions
- EHRs
- electronic health records
- FDA
- Food and Drug Administration
- FET
- Fisher’s exact test
- GI
- gastrointestinal
- ICD9
- International Statistical Classification of Diseases and Related Health Problems 9-CM
- MIMIC-III
- Medical Information Mart for Intensive Care III
- NOS
- Not otherwise specified
- PTAE
- potential transfusion adverse event
- RD
- rate difference
- RR
- rate ratio
- T
- group of transfusion admissions
- TACO
- transfusion associated circulatory overload
- TAE
- transfusion adverse event
- TRALI
- transfusion related acute lung injury
